Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
608 injection in moderate-to-severe plaque psoriasis (phase II)
CTR20210266Phase 2Completed
- Sponsor
- Henlius
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of 608 in plaque psoriasis, sponsored by Henlius. Started Apr 2021; status: completed.
02
Drugs
608
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on CTR20210266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210266.